Natural history and staging of chronic myelogenous leukemia

Research output: Contribution to journalReview article

Abstract

The natural history of CML has changed in recent years, partly due to earlier diagnosis but mostly as a consequence of the availability of effective therapies that have the potential to eradicate the Ph chromosomepositive clone. Highly effective therapy with imatinib has changed the prognostic significance of clinical features traditionally associated with poor outcome. Achieving a complete cytogenetic response and a major molecular response early during the course of therapy with imatinib may be the most important factor in determining long-term outcome. Therefore, treatment modalities that increase the probability of achieving this goal should be pursued.

Original languageEnglish (US)
Pages (from-to)569-584
Number of pages16
JournalHematology/Oncology Clinics of North America
Volume18
Issue number3
DOIs
StatePublished - Jun 1 2004
Externally publishedYes

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Natural History
Cytogenetics
Early Diagnosis
Therapeutics
Clone Cells
Imatinib Mesylate

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Natural history and staging of chronic myelogenous leukemia. / Cortes, Jorge.

In: Hematology/Oncology Clinics of North America, Vol. 18, No. 3, 01.06.2004, p. 569-584.

Research output: Contribution to journalReview article

@article{57eb0b4ee2a44a7c8b1b5c9562edf7bc,
title = "Natural history and staging of chronic myelogenous leukemia",
abstract = "The natural history of CML has changed in recent years, partly due to earlier diagnosis but mostly as a consequence of the availability of effective therapies that have the potential to eradicate the Ph chromosomepositive clone. Highly effective therapy with imatinib has changed the prognostic significance of clinical features traditionally associated with poor outcome. Achieving a complete cytogenetic response and a major molecular response early during the course of therapy with imatinib may be the most important factor in determining long-term outcome. Therefore, treatment modalities that increase the probability of achieving this goal should be pursued.",
author = "Jorge Cortes",
year = "2004",
month = "6",
day = "1",
doi = "10.1016/j.hoc.2004.03.011",
language = "English (US)",
volume = "18",
pages = "569--584",
journal = "Hematology/Oncology Clinics of North America",
issn = "0889-8588",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Natural history and staging of chronic myelogenous leukemia

AU - Cortes, Jorge

PY - 2004/6/1

Y1 - 2004/6/1

N2 - The natural history of CML has changed in recent years, partly due to earlier diagnosis but mostly as a consequence of the availability of effective therapies that have the potential to eradicate the Ph chromosomepositive clone. Highly effective therapy with imatinib has changed the prognostic significance of clinical features traditionally associated with poor outcome. Achieving a complete cytogenetic response and a major molecular response early during the course of therapy with imatinib may be the most important factor in determining long-term outcome. Therefore, treatment modalities that increase the probability of achieving this goal should be pursued.

AB - The natural history of CML has changed in recent years, partly due to earlier diagnosis but mostly as a consequence of the availability of effective therapies that have the potential to eradicate the Ph chromosomepositive clone. Highly effective therapy with imatinib has changed the prognostic significance of clinical features traditionally associated with poor outcome. Achieving a complete cytogenetic response and a major molecular response early during the course of therapy with imatinib may be the most important factor in determining long-term outcome. Therefore, treatment modalities that increase the probability of achieving this goal should be pursued.

UR - http://www.scopus.com/inward/record.url?scp=3242808935&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3242808935&partnerID=8YFLogxK

U2 - 10.1016/j.hoc.2004.03.011

DO - 10.1016/j.hoc.2004.03.011

M3 - Review article

C2 - 15271393

AN - SCOPUS:3242808935

VL - 18

SP - 569

EP - 584

JO - Hematology/Oncology Clinics of North America

JF - Hematology/Oncology Clinics of North America

SN - 0889-8588

IS - 3

ER -